NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SOTRADECOL (sodium tetradecyl sulfate) by Viatris (2) is clinical pharmacology sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Approved for the treatment of small uncomplicated varicose veins of the lower extremities. First approved in 1946.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sotradecol is a sclerosing agent administered by intravenous injection that treats small uncomplicated varicose veins of the lower extremities. It works by inducing intimal inflammation and thrombus formation within the injected vein, leading to partial or complete vein obliteration through subsequent fibrous tissue formation. This mechanism makes it a first-line option for patients seeking minimally invasive varicose vein management.
LOE Approaching
As an established product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely small and focused on defending market share against generic entrants rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration…
Career Relevance
Working on Sotradecol offers limited career growth given the zero linked job openings and approaching loss of exclusivity. This represents a sunset or maintenance-mode product where career progression opportunities are minimal and responsibilities center on defensive market strategy rather than innovation.
Worked on SOTRADECOL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.